

FIGURE 2: Chemical structure comparison between coelenterazine, enduRen and viviRen






FIGURE 3: Comparison of injection profiles between coelenterazine and viviRen in mice


viviRen
intravenously



Coelenterazine
Intraperitoneally



Coelenterazine
intravenously







Figure 5: Comparison of intravenous vs subcutaneous injection of viviRen in mice

viviRen
intravenously



viviRen
subcutaneously




Figure 6: Imaged ROS levels follow organ-specific patterns after irradiation with 8.68 Gy.





Figure 7: Imaged ROS levels in Total Body Imaging of ICR Mice, Caspase 3/7 in plasma during six days after irradiation with 8.68 Gy; PrC-210 treatment pre- and post-irradiation significantly suppresses Caspase 3/7







Figure 8: Imaged ROS levels (A), MDA (B) and Caspase 1 (C) levels in mouse brain after irradiation with 8.68 Gy

Figure 9: Caspase 8 and Caspase 3/7 levels follow imaged ROS levels after irradiation with 8.68 Gy, both with and without PrC-210 treatment






Figure 10: Correlation between imaged ROS in (A) and Onset of Disease and Hind-limb Paralysis in (B) in SOD1^{G93A} mice




Figure 11: Correlation between imaged whole-body free-radicals with viviRen (A) with different dosages of PrC-210 given 30 min before radiation, and (B) PrC-210 given 30min after radiation immediately before free-radicals imaging

